Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Pierre Fabre S.A.. (2/3/16). "Press Release: The Pierre Fabre Group Unveils Pierre Fabre Fund for Innovation. A New and Different Open Innovation Program". Castres.

Organisations Organisation Pierre Fabre Fund for Innovation
  Organisation 2 Alize RP (Public Relations)
Products Product pharmaceutical
  Product 2 venture capital
Persons Person Parmentier, Bertrand (Pierre Fabre 201602–201806 Group CEO RETIRED 6/18)
  Person 2 Audoly, Laurent (Kymera Thearapeutics 201710– CEO before Pierre Fabre SVP RnD before Pieris 201006–2010307 CSO)

> Pierre Fabre will accompany biotech companies, startups and research laboratories specialized in oncology, onco-dermatology or dermatology, primarily in France and Europe

> This program aims at speeding up the development process of new products currently at advanced preclinical stage or at early clinical stage

> Pierre Fabre support will consist in sharing expertise or financial contributions conditioned to the reaching of key milestones in the innovation process

Pierre Fabre, the 2nd largest French independent pharmaceutical group, have announced the launch of Pierre Fabre Fund for Innovation, a new Open Innovation initiative targeting biotech companies, startups and research laboratories (public or private) specialized in oncology or dermatology, two of the core therapeutic activities of Pierre Fabre R&D.

Pierre Fabre Fund for Innovation will support R&D projects either within 24 months from reaching clinical development or at early stage of clinical development. The support will consist of diverse forms of collaboration: sharing Pierre Fabre’s expertise over the full pharmaceutical value chain, co-financing of the research program, taking minority equity participation or negotiating license agreements. The combination of diverse forms of support is also conceivable. Pierre Fabre’s support on the long term will be conditioned to the reaching of key milestones in the innovation process.

Open to all international partnership opportunity, the main goal for Pierre Fabre Fund for Innovation is to help innovative companies located in France or in Europe, at a time when many European biotech companies, startups and research laboratories often lack the internal capabilities expertise to move on from discovery to proof of concept, or lack financial resources to turn their projects into reality. Pierre Fabre’s expertise and capabilities made available to its future partners include pharmacology, new chemical entities, biotherapies, immunotherapy, translational medicine, preclinical and clinical development, production of clinical batches, market access as well as market and regulatory strategy.

Pierre Fabre Fund for Innovation will be led by a Steering Committee comprised of Bertrand Parmentier, Group CEO, Frédéric Duchesne, Pharmaceuticals CEO, Luc Péligry, Group CFO, Frédéric Desdouits, Business Development Director and Laurent Audoly, Pharmaceuticals R&D Director. Laurent Audoly, as the Project Managing Partner, will take the lead of the operational management of the program. This deliberately restricted and executive governance will ensure quick and customized feedbacks to applicants. .

“With Pierre Fabre Fund for Innovation we have a dual purpose in mind. Firstly, we want to help speed up the development process of new molecules from preclinical to clinical phases, benefiting both their discoverers and the patients. In addition, Pierre Fabre Fund for Innovation’s long-term ambition is to foster our innovation process through an approach of co-construction with biotech companies, startups and research laboratories specialized in oncology, onco-dermatology or dermatology. It is therefore an innovative and collaborative initiative that falls within the framework of our Open Innovation strategy”, commented Bertrand Parmentier, Pierre Fabre Group CEO.

“Though many innovative companies discover technologies or molecules with real therapeutic benefits, some fail along the way due to a lack of resources to move effectively from discovery to development phase. With Pierre Fabre Innovation Fund, we intend to support these new businesses by giving them access to our scientific, medical, technical and industrial capabilities as well as to additional financial resources. We will eventually help them maximize their odds of success,” added Frédéric Duchesne, Pierre Fabre Pharmaceuticals CEO.

Starting today, project initiators can contact Pierre Fabre Fund for Innovation in two ways:

• Visit our website,, section « Partnership and Open Innovation »
• E-mail us directly at

About Pierre Fabre

Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company founded in 1961 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion Euros* in 2015, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns subsidiaries in 43 countries. In 2015, the company allocated 16 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.

Pierre Fabre’s oncology expertise is based on 3 decades of experience in the discovery, development and global commercialization of innovative cancer drugs including monoclonal antibodies and natural cytotoxic agents. The company performs its oncology, onco-dermatology and dermatology R&D in two major research centres: the Pierre Fabre Immunology Centre (CIPF) based in Saint-Julien-en-Genevois (France) and the Pierre Fabre Research Institute (IRPF) located on the Toulouse-based Oncopole campus. The latter is officially recognized by the French government as a National Center of Excellence for cancer research.

Pierre Fabre laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CRNS, Inserm, …), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay,…), biotech companies (Array, BioPharma, AbCheck, Cellectar, …) and international pharmaceutical laboratories (Allergan, Merck & Co., Abbvie, Maruho, …).

Through the Group’s controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 7.8% of the remaining shares are held by the company’s employees and balance is held as treasury stock.
AFNOR Certification has assessed the Corporate Social Responsibility policy of Pierre Fabre as “confirmed” (AFAQ 26000).

To learn more, please go to
You can also join us on Twitter and Facebook.

*2015 financial results currently being audited

Press Contact:

Valérie Roucoules
Pierre Fabre
Deputy Director Media Relations
Tel.: +33 1 49 10 83 84 / + 33 6 20 88 61 65

Caroline Carmagnol
Florence Portejoie
Wendy Rigal
Tel.: + 33 1 44 54 36 66

Record changed: 2018-05-15


Picture [LSUS] – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top